JP2008515780A - 抗ＦｃγＲＩＩＢレセプター抗体およびその使用 - Google Patents

抗ＦｃγＲＩＩＢレセプター抗体およびその使用 Download PDF

Info

Publication number
JP2008515780A
JP2008515780A JP2007530387A JP2007530387A JP2008515780A JP 2008515780 A JP2008515780 A JP 2008515780A JP 2007530387 A JP2007530387 A JP 2007530387A JP 2007530387 A JP2007530387 A JP 2007530387A JP 2008515780 A JP2008515780 A JP 2008515780A
Authority
JP
Japan
Prior art keywords
antibody
fcγriib
binding polypeptide
ige
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007530387A
Other languages
English (en)
Japanese (ja)
Inventor
アンドリュー シー． チャン，
ロバート エル． シールズ，
ローレン ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2008515780A publication Critical patent/JP2008515780A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
JP2007530387A 2004-09-02 2005-09-01 抗ＦｃγＲＩＩＢレセプター抗体およびその使用 Pending JP2008515780A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60685104P 2004-09-02 2004-09-02
PCT/US2005/031281 WO2006028956A2 (en) 2004-09-02 2005-09-01 Anti-fc-gamma riib receptor antibody and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011211535A Division JP5729826B2 (ja) 2004-09-02 2011-09-27 抗ＦｃγＲＩＩＢレセプター抗体およびその使用

Publications (1)

Publication Number Publication Date
JP2008515780A true JP2008515780A (ja) 2008-05-15

Family

ID=36036863

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007530387A Pending JP2008515780A (ja) 2004-09-02 2005-09-01 抗ＦｃγＲＩＩＢレセプター抗体およびその使用
JP2011211535A Expired - Lifetime JP5729826B2 (ja) 2004-09-02 2011-09-27 抗ＦｃγＲＩＩＢレセプター抗体およびその使用
JP2013265432A Withdrawn JP2014058566A (ja) 2004-09-02 2013-12-24 抗ＦｃγＲＩＩＢレセプター抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011211535A Expired - Lifetime JP5729826B2 (ja) 2004-09-02 2011-09-27 抗ＦｃγＲＩＩＢレセプター抗体およびその使用
JP2013265432A Withdrawn JP2014058566A (ja) 2004-09-02 2013-12-24 抗ＦｃγＲＩＩＢレセプター抗体およびその使用

Country Status (14)

Country Link
US (1) US20060073142A1 (enExample)
EP (1) EP1786836A2 (enExample)
JP (3) JP2008515780A (enExample)
KR (1) KR101247908B1 (enExample)
CN (1) CN101052653A (enExample)
AU (1) AU2005282720B2 (enExample)
BR (1) BRPI0515589A (enExample)
CA (1) CA2577405A1 (enExample)
IL (1) IL181186A (enExample)
NO (1) NO20071717L (enExample)
NZ (1) NZ553118A (enExample)
RU (1) RU2404991C2 (enExample)
WO (1) WO2006028956A2 (enExample)
ZA (1) ZA200701783B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502000A (ja) * 2008-09-05 2012-01-26 ズップレモル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ細胞媒介性多発性硬化症の治療のための物質および方法
JP2012520309A (ja) * 2009-03-11 2012-09-06 プロメディオール， インコーポレイテッド 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅｄｉｓｏｒｄｅｒ）に対する処置および診断方法
JP2012520310A (ja) * 2009-03-11 2012-09-06 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
JP2013529190A (ja) * 2010-04-23 2013-07-18 ジェネンテック， インコーポレイテッド ヘテロ多量体タンパク質の産生
JP2021533806A (ja) * 2018-08-23 2021-12-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗ｆｃイプシロン−ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
JP2022552805A (ja) * 2019-10-01 2022-12-20 エプシロゲン エルティーディー ハイブリッド抗体
US12030926B2 (en) 2014-05-06 2024-07-09 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) * 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US20050260213A1 (en) * 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
JP4459810B2 (ja) * 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) * 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP1587540B1 (en) * 2003-01-09 2021-09-15 MacroGenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
CA2534959A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2577082A1 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
CA2590935C (en) * 2004-12-15 2014-09-30 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1916997B1 (en) 2005-08-05 2018-04-18 Amgen Inc. Stable aqueous protein pharmaceutical formulations and their preparation
PL1919503T3 (pl) * 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
JP2009529331A (ja) * 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP1870422A1 (en) * 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
EP2505209A1 (en) * 2006-06-26 2012-10-03 MacroGenics, Inc. Fcgamma-RIIB-specific antibodies and methods of the use thereof
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US8247370B2 (en) 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
MX2009013816A (es) 2007-06-21 2010-02-24 Macrogenics Inc Diacuerpos covalentes y usos de los mismos.
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2234641B1 (en) 2008-01-03 2015-08-19 Genmab A/S Monoclonal antibodies against cd32b
JP5785490B2 (ja) 2008-04-02 2015-09-30 マクロジェニクス，インコーポレーテッド Ｂｃｒ複合体特異的抗体およびその使用方法
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
ES2675730T3 (es) * 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
CN102131517B (zh) * 2008-06-27 2014-12-17 津莫吉尼蒂克斯公司 可溶性杂合Fc γ受体和相关的方法
KR20160005143A (ko) * 2009-05-13 2016-01-13 젠자임 코포레이션 항-인간 ｃｄ52 면역글루불린
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
DK2987803T3 (en) 2009-06-17 2018-12-17 Promedior Inc SAP variants and their application
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781519A1 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
NZ599600A (en) * 2009-10-26 2015-04-24 Genentech Inc Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
US10017762B2 (en) 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
CA2818712C (en) * 2010-11-24 2020-11-10 Government Of The U.S.A. Represented By The Secretary, Dept. Of Health & Human Services Compositions and methods for treating or preventing lupus
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9868786B2 (en) * 2011-04-12 2018-01-16 University Of Cincinnati Methods for suppressing allergic reactions
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2971444T3 (es) 2011-10-11 2024-06-05 F Hoffmann Lar Roche Ag Ensamblaje mejorado de anticuerpos biespecíficos
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
MX354717B (es) 2012-03-16 2018-03-16 Covagen Ag Moleculas de union novedosas con actividad antitumoral.
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
WO2014041072A1 (en) 2012-09-14 2014-03-20 F. Hoffmann-La Roche Ag Method for the production and selection of molecules comprising at least two different entities and uses thereof
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
AU2015303142B2 (en) * 2014-08-13 2020-08-06 Suppremol Gmbh Novel antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
PL3227332T3 (pl) 2014-12-03 2020-06-15 F. Hoffmann-La Roche Ag Wielospecyficzne przeciwciała
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CA2975875A1 (en) 2015-02-04 2016-08-11 Genentech, Inc. Mutant smoothened and methods of using the same
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
MY198114A (en) 2016-04-15 2023-08-04 Macrogenics Inc Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
JP7050333B2 (ja) 2017-03-24 2022-04-08 全薬工業株式会社 抗ＩｇＭ／Ｂ細胞表面抗原二重特異性抗体
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
JP7658905B2 (ja) * 2019-01-23 2025-04-08 ジェネンテック， インコーポレイテッド 真核宿主細胞において多量体タンパク質を産生する方法
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
WO2021006375A1 (ko) * 2019-07-08 2021-01-14 (주)지아이이노베이션 Ige fc 수용체의 알파 서브유닛의 세포외 도메인을 포함하는 시알산 함량이 높은 폴리펩티드 이량체 및 이를 포함하는 약학적 조성물
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
KR20240116743A (ko) * 2021-11-09 2024-07-30 한양대학교 산학협력단 Fc 변이체를 포함하는 이종이합체 및 이의 제조방법
CN118317976A (zh) * 2021-12-22 2024-07-09 上海齐鲁制药研究中心有限公司 针对FcγRIIA的结合分子及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) * 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
DE3127674A1 (de) * 1981-07-14 1983-02-24 Rheinmetall GmbH, 4000 Düsseldorf Verfahren und vorrichtung zum belegen einer zielflaeche mit munition
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP0656789B1 (en) * 1992-08-21 1997-12-17 Genentech, Inc. Method for treating a lfa-1-mediated disorder
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5714338A (en) * 1993-12-10 1998-02-03 Genentech, Inc. Methods for diagnosis of allergy
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) * 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5736168A (en) * 1996-09-17 1998-04-07 Star Container Co. Blow mold with replaceable inserts
US5731156A (en) * 1996-10-21 1998-03-24 Applied Imaging, Inc. Use of anti-embryonic hemoglobin antibodies to identify fetal cells
JP2001211886A (ja) * 2000-02-07 2001-08-07 Japan Science & Technology Corp Ｌ−体及びｄ−体アミノ酸を輸送するナトリウム非依存性小型中性アミノ酸トランスポーター及びその遺伝子
AU5345901A (en) * 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
WO2002088317A2 (en) * 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US20050260213A1 (en) * 2004-04-16 2005-11-24 Scott Koenig Fcgamma-RIIB-specific antibodies and methods of use thereof
JP4459810B2 (ja) * 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
CA2565874C (en) * 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502000A (ja) * 2008-09-05 2012-01-26 ズップレモル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ細胞媒介性多発性硬化症の治療のための物質および方法
JP2012520309A (ja) * 2009-03-11 2012-09-06 プロメディオール， インコーポレイテッド 過敏性障害（ｈｙｐｅｒｓｅｎｓｉｔｉｖｅｄｉｓｏｒｄｅｒ）に対する処置および診断方法
JP2012520310A (ja) * 2009-03-11 2012-09-06 プロメディオール， インコーポレイテッド 自己免疫障害に対する処置方法
JP2013529190A (ja) * 2010-04-23 2013-07-18 ジェネンテック， インコーポレイテッド ヘテロ多量体タンパク質の産生
US9637557B2 (en) 2010-04-23 2017-05-02 Genentech, Inc. Production of heteromultimeric proteins
US12030926B2 (en) 2014-05-06 2024-07-09 Genentech, Inc. Production of heteromultimeric proteins using mammalian cells
JP2021533806A (ja) * 2018-08-23 2021-12-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 抗ｆｃイプシロン−ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
JP2023171909A (ja) * 2018-08-23 2023-12-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
JP7402223B2 (ja) 2018-08-23 2023-12-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
JP7541167B2 (ja) 2018-08-23 2024-08-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
US12441797B2 (en) 2018-08-23 2025-10-14 Regeneron Pharmaceuticals, Inc. Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereof
JP2022552805A (ja) * 2019-10-01 2022-12-20 エプシロゲン エルティーディー ハイブリッド抗体

Also Published As

Publication number Publication date
KR101247908B1 (ko) 2013-03-26
BRPI0515589A (pt) 2008-07-29
RU2404991C2 (ru) 2010-11-27
WO2006028956A9 (en) 2006-05-18
AU2005282720B2 (en) 2011-08-04
JP2011256213A (ja) 2011-12-22
JP2014058566A (ja) 2014-04-03
EP1786836A2 (en) 2007-05-23
WO2006028956A3 (en) 2006-08-31
IL181186A0 (en) 2007-07-04
ZA200701783B (en) 2009-10-28
KR20070057852A (ko) 2007-06-07
NO20071717L (no) 2007-05-31
IL181186A (en) 2012-01-31
WO2006028956A2 (en) 2006-03-16
JP5729826B2 (ja) 2015-06-03
AU2005282720A1 (en) 2006-03-16
CN101052653A (zh) 2007-10-10
CA2577405A1 (en) 2006-03-16
US20060073142A1 (en) 2006-04-06
RU2007111941A (ru) 2008-10-10
NZ553118A (en) 2009-12-24

Similar Documents

Publication Publication Date Title
JP5729826B2 (ja) 抗ＦｃγＲＩＩＢレセプター抗体およびその使用
US7662926B2 (en) Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) Anti-FC-gamma RIIB receptor antibody and uses therefor
JP6312092B2 (ja) 変化したエフェクター機能を有するポリペプチド変異体
CN100460421C (zh) 免疫球蛋白变体及其用途
JP2002510481A (ja) 抗体変異体及びその断片
CN104474546A (zh) 用于疾病治疗的针对IL-1β和IL-18的抗体
PL212899B1 (pl) Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku
JP2006036779A (ja) ヒト化抗ＣＤ１１ａ抗体
WO2007117600A2 (en) Combination therapy for treating autoimmune diseases
JP2012517806A (ja) ヒト化抗ｃｄ２０抗体および使用方法
US20240254234A1 (en) PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
US20190153096A1 (en) Cd3/cd33 bispecific binding molecules
US20130149308A1 (en) Antibodies to il-1beta and il-18, for treatment of disease
MX2007002571A (en) Anti-fc-gamma riib receptor antibody and uses therefor
HK1113492A (en) Anti-fc-gamma riib receptor antibody and uses therefor
HK1186194A (en) Antibodies to il-1beta and il-18, for treatment of disease
HK1129406B (en) Immunoglobulin variants and uses thereof
HK1129406A (zh) 免疫球蛋白變體及其用途
HK1129407A (en) Immunoglobulin variants and uses thereof
HK1129405A (en) Immunoglobulin variants and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110729

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110830

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120809